hotspot -WSS

hotspot

author：focus 2025-09-06 04:41:37 - browse：94892

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Congress must protect the remaining independent doctors

WSS

Congress considering partial increase for doctor pay in Medicare

Abbott's new heart device gets FDA advisory panel nod

Heart attack and stroke risk calculators need revising

Supreme Court strikes down use of affirmative action

Virginia high school admissions case could be legal follow

Jerome Adams on the need for new antivirals for Covid

hotspot

hotspot

Wikipedia

Supreme Court strikes down use of affirmative action

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Supreme Court strikes down use of affirmative action

Jerome Adams on the need for new antivirals for Covid

Report cites 'urgent' need to recruit more diverse clinical trial participants

Alkermes shareholders re

Apple is now the first public company to be valued at $3 trillion

Supreme Court strikes down use of affirmative action

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Jerome Adams on the need for new antivirals for Covid

Activists slam private health insurers over coverage restrictions

Novavax promises a turnaround & Lilly roils the obesity market

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Continuity nursing helped my family in our darkest PICU moments

hotspot

entertainment

explore

Wikipedia